Christopher Holmes None;
Naomi Wijesingha None;
Syed Ahmer Raza None;
Tom Taylor None;
Ahmed Hagag boehringer ingelheim, Code E (Employment);
Sophie Riedl None;
Julia Mai None;
Daniel Rueckert IXICO Plc , Code I (Personal Financial Interest), IXICO Plc, Code O (Owner);
Hrvoje Bogunovic Apellis, Heidelberg Engineering, Retinsight, Code F (Financial Support), Apellis, Bayer , Code R (Recipient);
Hendrik Scholl Alnylam Pharmaceuticals Inc., Gerson Lehrman Group Inc., Guidepoint Global, LLC, Tenpoint Therapeutics, Code C (Consultant/Contractor), Boehringer Ingelheim Pharma GmbH & Co, Droia NV, Eluminex Biosciences, Gyroscope Therapeutics Ltd., Janssen Research & Development, LLC (Johnson & Johnson), Okuvision GmbH, ReVision Therapeutics Inc., Saliogen Therapeutics Inc, Code S (non-remunerative);
Ursula Schmidt-Erfurth Topcon, Stealth BioTherapeutics, Novartis, Heidelberg Engineering, Boehringer Ingelheim, Aviceda, Apellis, Abbvie, Code C (Consultant/Contractor), Genentech, Kodiak, Novartis, Roche, RetinSight, Code F (Financial Support), RetinSight, Code P (Patent);
Lars Fritsche None;
Andrew Lotery Allergan , Apellis , Complement Therapeutics , Eyebio , Gyroscope/Novartis, Tarsus Pharmaceuticals, Code C (Consultant/Contractor);
Sobha Sivaprasad AbbVie, Amgen, Apellis, Bayer, Biogen, Boehringer Ingelheim, Novartis, Eyebiotech, Eyepoint Phamaceuticals, Janssen Pharmaceuticals, Nova Nordisk, Optos, Ocular Therapeutix, Kriya Therapeutics, OcuTerra, Roche, Stealth Biotherapeutics and Sanofi. , Code F (Financial Support)